Stay updated with breaking news from Charlotte russel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Public File - KVNO kvno.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kvno.org Daily Mail and Mail on Sunday newspapers.
Published: Jan 01, 2021 By Alex Keown ImmunityBio – Fabio M. Benedetti was named chief strategy officer of California-based ImmunityBio. Benedetti will oversee life-cycle management, pipeline and commercial strategy, including medical affairs. Following the completion of ImmunityBio’s proposed merger with NantKwest, Benedetti is expected to assume the role of chief strategy officer of the combined company. Benedetti most recently served as chief medical officer for Apollomics, Inc., where he led global clinical development programs including clinical strategy, clinical development, and regulatory affairs. He also previously served as Global CMO at Taiho Pharmaceutical Company, Ltd. and CMO for Taiho Oncology, Inc. Prior to Taiho, he held the positions of senior vice president of Clinical Oncology and CMO at Geron Corporation. He also held roles at Onyx Pharmaceuticals, Millennium Pharmaceuticals, Roche and Bristol-Myers Squibb. ....
Alligator Bioscience recruits new Chief Medical Officer LUND, Sweden, Dec. 29, 2020 /PRNewswire/ Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the company has appointed Dr Christina Reimer as Chief Medical Officer. She most recently comes from a position as Senior Medical Director at Ferring Pharmaceuticals in Copenhagen. Dr Reimer will replace Dr Charlotte Russel and be overall medically responsible for Alligator s drug development candidates, with an emphasis on bringing mitazalimab and ATOR-1017 into Phase II efficacy studies. She will report to Head of R&D, EVP Malin Carlsson, and be part of the management team. I am very pleased with the successful recruitment of Christina Reimer to Alligator. Her international experience in leading clinical development and in building development organizations will significantly strengthen our clinical capacity. This is crucial in the phase we are in now, with two products on the way to Phase II and ....